Core Viewpoint - The company, Baize Medical (02609), has been selected to be included in various Hang Seng Index series, effective from September 8, 2025, reflecting increased investor recognition of its operational performance and growth potential [1] Group 1: Inclusion in Hang Seng Index - Baize Medical will be included in the Hang Seng Composite Index, Hang Seng Composite Industry Index - Healthcare, Hang Seng Composite Small Cap Index, Hang Seng Healthcare Index, and other related indices [1] - The Hang Seng Composite Index covers the top 95% of total market capitalization of companies listed on the Hong Kong Stock Exchange, serving as a comprehensive market benchmark [1] Group 2: Impact on Market Presence - Inclusion in the Hang Seng Composite Index will qualify the company's shares for trading through the Hong Kong Stock Connect programs, enhancing accessibility for mainland Chinese investors [1] - The board anticipates that this inclusion will increase the company's visibility in the capital markets, improve trading liquidity, and further enhance its investment value [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任 何 損 失 承 擔 任 何 責 任。 Bayzed Health Group Inc 佰澤醫療集團 （根據開曼群島法律註冊成立的有限公司） （股份代號：2609） 自願公告 本公司獲納入恆生指數系列成份股 本 公 告 乃 由 佰 澤 醫 療 集 團（「本公司」，連 同 其 附 屬 公 司 統 稱 為「本集團」） 自 願 作 出，旨 在 知 會 本 公 司 股 東 及 投 資 者 有 關 本 公 司 之 最 新 業 務 發 展。 本 公 司 董 事 會（「董事會」）欣 然 宣 佈，根 據 恒 生 指 數 有 限 公 司 於2025年8月 22日 公 佈 的 恒 生 指 數 系 列 季 度 檢 討 結 果，本 公 司 已 獲 選 並 將 納 入 包 括 但 不 限 於 下 述 恒 生 指 數 系 列 成 份 股，自2025年9月8日 起 生 效： 1. 恒 生 綜 合 指 數； ...

Group 1 - The Hang Seng Index Company announced the inclusion of Baize Medical (02609) in the Hang Seng Composite Index, effective after market close on September 5, 2025, and effective from September 8, 2025 [1] - Baize Medical is likely to be included in the Hong Kong Stock Connect due to meeting various criteria such as market capitalization, liquidity, and listing duration [1] - Baize Medical plans to hold a board meeting on August 28 to consider and approve its interim results [1] Group 2 - Baize Medical is a major Chinese oncology medical group engaged in investment and provision of medical services, operating eight hospitals across Beijing, Tianjin, Shanxi, Anhui, and Henan provinces [2] - The group focuses on providing comprehensive oncology medical services through direct equity ownership in six for-profit hospitals and management rights in two non-profit hospitals [2] Group 3 - Baize Medical, in collaboration with renowned hospitals, published the "Oncology Rehabilitation Expert Consensus (2025)" in a prestigious academic journal, emphasizing the importance of oncology rehabilitation in improving patient quality of life [1] - The consensus outlines the target population for oncology rehabilitation, assessment standards, and five key rehabilitation strategies, highlighting the role of multidisciplinary teams (MDT) in the rehabilitation process [1]

Core Insights - The Hang Seng Index Company announced the inclusion of Baize Medical (02609) in the Hang Seng Composite Index, effective after market close on September 5, 2025, with trading starting on September 8, 2025 [1] - Baize Medical is expected to be included in the Hong Kong Stock Connect due to meeting various criteria such as market capitalization, liquidity, and listing duration [1] - Baize Medical plans to hold a board meeting on August 28 to consider and approve its interim results [1] Company Overview - Baize Medical is a major Chinese oncology medical group engaged in investment and provision of medical-related services [2] - The group operates and manages eight hospitals across Beijing, Tianjin, Shanxi, Anhui, and Henan provinces, focusing on providing comprehensive oncology medical services [2] Research and Development - Baize Medical, in collaboration with renowned hospitals, published the "Oncology Rehabilitation Expert Consensus (2025)" in a prestigious academic journal, emphasizing the importance of cancer rehabilitation in improving patient quality of life and reducing treatment side effects [1] - The consensus outlines the target population for cancer rehabilitation, assessment standards, and five key rehabilitation strategies, highlighting the role of multidisciplinary teams (MDT) in the rehabilitation process [1]

Core Viewpoint - Baize Medical (02609) has seen its stock price rise over 8%, reaching a new high of 7.13 HKD, driven by positive developments in its mid-term performance and the publication of a significant consensus on cancer rehabilitation [1] Company Summary - Baize Medical is a major Chinese oncology medical group engaged in investment and provision of medical-related services, operating eight hospitals across Beijing, Tianjin, Shanxi, Anhui, and Henan provinces [1] - The company has direct equity ownership in six private for-profit hospitals and management rights in two private non-profit hospitals, focusing on providing comprehensive cancer care services [1] Industry Summary - The consensus on cancer rehabilitation, developed in collaboration with renowned hospitals, emphasizes the importance of rehabilitation in improving patient quality of life, reducing treatment side effects, and promoting functional recovery [1] - The consensus outlines the target population and goals for cancer rehabilitation, proposing systematic assessment standards and five actionable rehabilitation strategies [1] - It highlights the necessity of a multidisciplinary team (MDT) approach in cancer rehabilitation, which should encompass pre-rehabilitation, intervention during treatment, and long-term recovery [1]

格隆汇8月13日丨佰泽医疗(02609.HK)公告，谨定于2025年8月26日(星期二)举行董事会会议，以考虑及 通过集团截至2025年6月30日止6个月中期业绩，以及处理其他事项。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 香 港，2025年8月13日 於 本 公 告 日 期，董 事 會 包 括 執 行 董 事 趙 永 凱 先 生、徐 旭 女 士、陳 昊 陽 博 士、盧 繼 忠 先 生 及 馮 宇 先 生；以 及 獨 立 非 執 行 董 事 陳 學 良 先 生、劉 爽 女 士 及 郭 衛 博 士。 董事會召開日期 佰 澤 醫 療 集 團（「本公司」及 其 附 屬 公 司「本集團」）董 事 會（「董事會」）茲 通 告 謹定於2025年8月26日（星 期 二）舉 行 董 事 會 會 議，以 考 慮 及 通 過 本 集 團 截 至2025年6月30日 止 六 個 月 之 中 期 業 績，以 及 處 理 其 他 事 項。 承董事會命 佰澤醫療集團 趙永凱先生 董事長兼執行董事 Bayzed Health Group Inc 佰澤醫療集團 （根據開曼群島法律註冊成立 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02609 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 1,318,466,823 | | | | 1,318,466,823 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 1,318,466,823 | | 0 | | 1,318,466,823 | 公司名稱: 佰澤醫療集團 （根據開曼群島法律註冊成立的有限公司） 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | ...

Core Viewpoint - Baize Medical has successfully launched its IPO on the Hong Kong Stock Exchange, demonstrating strong market confidence with a first-day stock price increase of over 42% [1] Group 1: IPO and Financial Performance - The company issued 133 million shares at an initial price of 4.22 HKD, raising approximately 562 million HKD for future development [1] - Revenue is projected to grow from 800 million CNY in 2022 to 1.19 billion CNY in 2024, reflecting a compound annual growth rate (CAGR) of 21.7% [2] - Gross profit is expected to increase from 80 million CNY to 210 million CNY during the same period, with a CAGR of 61.8% [2] - The company has crossed the breakeven point, achieving an adjusted net profit of 12.496 million CNY in 2024, confirming the sustainability of its business model [2] Group 2: Strategic Development and Market Position - Baize Medical is positioned as a leader in the full-cycle cancer service sector, utilizing a differentiated strategy of "early screening + treatment + rehabilitation" [1] - The company operates eight hospitals across five provinces, focusing on early cancer screening and rehabilitation, thereby enhancing its competitive edge [1] - The launch of the "Five Prescriptions for Cancer Rehabilitation" initiative and the publication of the "Cancer Rehabilitation Expert Consensus (2025)" highlight the company's commitment to advancing cancer rehabilitation services [3][4] Group 3: Market Opportunities and Future Outlook - The aging population and increasing cancer survival rates present significant growth potential in the cancer rehabilitation market [4] - Baize Medical's proactive approach positions it to capitalize on the expanding demand for cancer prevention and treatment services [4] - The favorable market conditions and the company's strategic initiatives are expected to accelerate its business expansion and enhance shareholder value [4]

Core Viewpoint - Baize Medical's successful debut on the Hong Kong Stock Exchange and the publication of the "Oncology Rehabilitation Expert Consensus (2025)" mark significant milestones for the company, emphasizing its focus on comprehensive cancer care services [1][2][4]. Group 1: Company Milestones - Baize Medical's stock price surged over 42% on its first trading day, reflecting strong investor confidence in its growth potential within the oncology sector [1]. - The "Oncology Rehabilitation Expert Consensus (2025)" introduces a new "full-cycle rehabilitation" framework, defining five key rehabilitation prescriptions and establishing the importance of multidisciplinary collaboration [2][4]. Group 2: Market Context - The oncology treatment sector is identified as a high-growth area due to increasing clinical demand and structural opportunities arising from the mismatch in China's healthcare resources [6]. - Current statistics indicate that China's five-year cancer survival rate is only 40.5%, significantly lower than the 67.1% in the U.S., highlighting the urgent need for improved cancer care resources [6]. Group 3: Policy and Industry Dynamics - Recent government policies aim to enhance private healthcare development, particularly in oncology, by guiding social capital into critical medical fields and reforming payment systems to create a fair environment for private hospitals [7]. - The number of private hospitals in China has grown from 20,977 in 2018 to 26,583 in 2023, with a projected increase to 44,063 by 2030, indicating a robust expansion in the private healthcare sector [7][8]. Group 4: Competitive Advantage - Baize Medical's strategy focuses on a full-cycle service model that integrates screening, diagnosis, treatment, and rehabilitation, creating a competitive edge in the oncology market [13][16]. - The company leads in early cancer screening capabilities among private oncology medical groups in China, with all its hospitals establishing specialized early cancer screening centers [15]. Group 5: Growth Strategy - Baize Medical plans to utilize approximately HKD 191 million (30.6% of net proceeds from its global offering) for acquiring quality hospital targets to enhance its network and specialized capabilities [21]. - The company is also investing around HKD 63.7 million (10.2% of proceeds) in upgrading its digital management systems to improve operational efficiency and patient management [22]. Group 6: Long-term Outlook - The combination of strategic acquisitions and digital technology integration is expected to drive Baize Medical's growth, positioning it well within the evolving oncology service landscape [18][22]. - The company's full-cycle service strategy aligns with national healthcare reforms aimed at enhancing cancer prevention and management, reinforcing its role as a key player in the industry [24][25].